Yesterday, the President & CEO of Cerus Corp (CERS), William Mariner Greenman, bought shares of CERS for $46K.
This recent transaction increases William Mariner Greenman’s holding in the company by 1.59% to a total of $3 million.
See today’s analyst top recommended stocks >>
Based on Cerus Corp’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $21.97 million and GAAP net loss of $18.79 million. In comparison, last year the company earned revenue of $17.02 million and had a GAAP net loss of $13.89 million. Currently, Cerus Corp has an average volume of 2.47M. The Company has a Price to Book ratio of 9.3200.
Starting in July 2018, CERS received 18 Buy ratings in a row.
The insider sentiment on Cerus Corp has been negative according to 33 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cerus Corp. engages in the research, development, and manufacture of biomedical and surgical products. The company produces blood system for platelets and plasma. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.
